28298171|t|Extended release of flurbiprofen from tromethamine - buffered HPMC hydrophilic matrix tablets
28298171|a|The pH - dependent solubility of a drug can lead to pH - dependent drug release from hydrophilic matrix tablets. Adding buffer salts to the formulation to attempt to mitigate this can impair matrix hydration and negatively impact drug release. An evaluation of the buffering of hydrophilic matrix tablets containing a pH - dependent solubility weak acid drug (flurbiprofen), identified as possessing a deleterious effect on hydroxypropyl methylcellulose (HPMC) solubility, swelling and gelation, with respect to drug dissolution and the characteristics of the hydrophilic matrix gel layer in the presence of tromethamine as a buffer was undertaken. The inclusion of tromethamine as an alkalizing agent afforded pH - independent flurbiprofen release from matrices based on both HPMC 2910 (E series) and 2208 (K series), while concomitantly decreasing the apparent critical effect on dissolution mediated by this drug with respect to the early pseudo-gel layer formation and functionality. Drug release profiles were unaffected by matrix pH-changes resulting from loss of tromethamine over time, suggesting that HPMC inhibited precipitation of drug from supersaturated solution in the hydrated matrix. We propose that facilitation of diffusion-based release of potentially deleterious drugs in hydrophilic matrices may be achieved through judicious selection of a buffering species.
28298171	0	16	Extended release	T079	C0868939
28298171	20	32	flurbiprofen	T109,T121	C0016377
28298171	38	50	tromethamine	T109,T121	C0041175
28298171	53	61	buffered	T121,T130	C0006353
28298171	62	66	HPMC	T109,T121	C0063242
28298171	67	78	hydrophilic	T080	C0475370
28298171	79	93	matrix tablets	T122	C0039225
28298171	98	100	pH	T081	C0020283
28298171	103	112	dependent	T169	C3244310
28298171	113	123	solubility	T080	C0037628
28298171	129	133	drug	T121	C1254351
28298171	146	148	pH	T081	C0020283
28298171	151	160	dependent	T169	C3244310
28298171	161	173	drug release	T070	C3850077
28298171	179	190	hydrophilic	T080	C0475370
28298171	191	205	matrix tablets	T122	C0039225
28298171	214	226	buffer salts	T121,T197	C1659042
28298171	234	245	formulation	T122	C0013058
28298171	249	256	attempt	T051	C1516084
28298171	260	268	mitigate	T067	C1553901
28298171	278	284	impair	T169	C0221099
28298171	285	301	matrix hydration	T067	C0596317
28298171	306	316	negatively	T033	C0205160
28298171	317	323	impact	T080	C4049986
28298171	324	336	drug release	T070	C3850077
28298171	341	351	evaluation	T058	C0220825
28298171	359	368	buffering	T121,T130	C0006353
28298171	372	383	hydrophilic	T080	C0475370
28298171	384	398	matrix tablets	T122	C0039225
28298171	412	414	pH	T081	C0020283
28298171	417	426	dependent	T169	C3244310
28298171	427	437	solubility	T080	C0037628
28298171	438	452	weak acid drug	T121	C1254351
28298171	454	466	flurbiprofen	T109,T121	C0016377
28298171	469	479	identified	T080	C0205396
28298171	483	493	possessing	T078	C3154893
28298171	496	514	deleterious effect	T080	C1280500
28298171	518	547	hydroxypropyl methylcellulose	T109,T121	C0063242
28298171	549	553	HPMC	T109,T121	C0063242
28298171	555	565	solubility	T080	C0037628
28298171	567	575	swelling	T067	C1522240
28298171	580	588	gelation	T067	C1522240
28298171	606	622	drug dissolution	T070	C3850077
28298171	631	646	characteristics	T080	C1521970
28298171	654	665	hydrophilic	T080	C0475370
28298171	666	682	matrix gel layer	T122	C0017243
28298171	690	698	presence	UnknownType	C0332443
28298171	702	714	tromethamine	T109,T121	C0041175
28298171	720	726	buffer	T121,T130	C0006353
28298171	747	756	inclusion	T080	C1512693
28298171	760	772	tromethamine	T109,T121	C0041175
28298171	779	795	alkalizing agent	T121	C0304463
28298171	805	807	pH	T081	C0020283
28298171	810	821	independent	T169	C0332291
28298171	822	834	flurbiprofen	T109,T121	C0016377
28298171	835	842	release	T079	C0868939
28298171	848	856	matrices	T167	C0439861
28298171	871	891	HPMC 2910 (E series)	T109,T121	C0063242
28298171	896	911	2208 (K series)	T109,T121	C0063242
28298171	919	932	concomitantly	T079	C0521115
28298171	933	943	decreasing	T033	C0442797
28298171	957	972	critical effect	T080	C1280500
28298171	976	987	dissolution	T070	C3850077
28298171	988	996	mediated	T054	C0086597
28298171	1005	1009	drug	T121	C1254351
28298171	1036	1062	pseudo-gel layer formation	T169	C1522492
28298171	1067	1080	functionality	T169	C0205245
28298171	1082	1103	Drug release profiles	T073	C1707824
28298171	1109	1119	unaffected	T077	C2986417
28298171	1123	1129	matrix	T167	C0439861
28298171	1130	1140	pH-changes	T033	C0243095
28298171	1156	1160	loss	T081	C1517945
28298171	1164	1176	tromethamine	T109,T121	C0041175
28298171	1177	1186	over time	T079	C1254367
28298171	1204	1208	HPMC	T109,T121	C0063242
28298171	1209	1218	inhibited	T080	C0311403
28298171	1219	1232	precipitation	T070	C0032931
28298171	1236	1240	drug	T121	C1254351
28298171	1246	1269	supersaturated solution	T167	C0037633
28298171	1277	1292	hydrated matrix	T067	C0596317
28298171	1310	1322	facilitation	T042	C0234112
28298171	1326	1341	diffusion-based	T070	C0012222
28298171	1342	1349	release	T079	C0868939
28298171	1365	1382	deleterious drugs	T121	C1254351
28298171	1386	1397	hydrophilic	T080	C0475370
28298171	1398	1406	matrices	T167	C0439861
28298171	1456	1473	buffering species	T121,T130	C0006353